SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maul Coin

Maul Coin is generating buzz as a community-driven project aiming to replicate the massive growth of previous viral memecoins through active social media raiding and a transparent developer-led approach. While the community is currently focused on overcoming technical hurdles like securing official charts and listings, members are heavily incentivized by the potential for 1000x gains and a movement-based ethos that rejects typical 'pump and dump' behavior.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is attracting significant community attention as traders debate its potential for a breakout, with many highlighting the upcoming Layla upgrade in May 2026 as a pivotal catalyst for increased utility and quantum resistance. While bulls point to resilient price action and the network's low-fee, peer-to-peer focus, ongoing discussions remain polarized between those expecting a major decoupling from Bitcoin and critics dismissing the asset due to historical performance concerns.

Nucor Corp. engages in the manufacture of steel products, and ferrous and non-ferrous materials. It operates through the following segments: Steel Mills, Steel Products, and Raw Materials. The Steel Mills segment consists of producing sheet, plate, structural, and bar steel. The Steel Products segment includes steel joists and joist girders, deck, fabricated concrete reinforcing, cold finished, fasteners, metal building systems, grating, tubular, piling products businesses, and wire mesh. The Raw Materials segment consists of direct reduced iron, and ferrous and nonferrous metals. The company was founded by Ransom E. Olds in 1905 and is headquartered in Charlotte, NC.

Nucor Corp.

Nucor is trending as investors react to the anticipated formalization of 25% tariffs on global steel and aluminum imports. The community is actively discussing how these protective measures may bolster domestic manufacturing demand and pricing power, with some participants expressing caution regarding potential inflationary impacts and global trade volatility.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is trending due to heightened investor focus on the upcoming PDUFA decision date for RP1, with market participants debating whether the resubmission successfully addresses previous FDA concerns or if a second Complete Response Letter is likely. The community remains deeply divided, with some traders citing unusual options volume and potential short-covering as bullish indicators, while skeptics warn of significant downside risk if the company fails to secure accelerated approval.

Oscar Health, Inc. is a healthcare insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is capturing significant investor attention as markets weigh the company's ambitious 2026 profitability guidance against its recent quarterly earnings miss. While the community remains deeply divided between those betting on long-term growth through AI-driven operational efficiency and skeptics concerned about medical loss ratios, retail traders are closely tracking the stock's volatility ahead of potential structural pivots in the healthcare sector.

SiriusXM Holdings, Inc. engages in the provision of audio entertainment. It operates through the Sirius XM and Pandora and Off-Platform segments. The Sirius XM segment features a wide range of content, including, music, sports, entertainment, comedy, talk and news channels, podcasts and infotainment services, all available in the United States on a subscription fee basis. The Pandora and Off-Platform segment generates a majority of its revenues from third parties advertising on the Pandora ad-supported service and other platforms. The company was founded on May 17, 1990, and is headquartered in New York, NY.

Sirius XM Holdings Inc.

Sirius XM Holdings Inc

Sirius XM Holdings is attracting intense investor attention as Berkshire Hathaway continues to aggressively increase its stake, signaling strong institutional confidence despite recent downward price pressure. The community is actively debating the company's valuation, dividend stability, and the potential impact of high short interest amid ongoing speculation regarding future content strategies and M&A activity.

Invesco DB US Dollar Index Bullish Fund - Common units of beneficial interest

Invesco DB US Dollar Index Bullish Fund

The Invesco DB US Dollar Index Bullish Fund is trending as market participants weigh conflicting signals between safe-haven demand amid rising Middle East geopolitical tensions and concerns over long-term fiscal deficits. Traders are actively debating the dollar's strength relative to precious metals and foreign currencies as they monitor key labor data and shifting central bank interest rate policies.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol-Myers Squibb is seeing increased investor attention as the company leverages a robust pipeline, including recent label expansions and the continued development of its oncology portfolio, to navigate patent cliffs. Market sentiment is bolstered by steady dividends and strategic collaborations, though traders remain focused on upcoming trial data readouts that will be critical for long-term growth and potential M&A activity.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is trending due to surging after-hours volume and unconfirmed speculation regarding a potential buyout, which has intensified community discussion about its valuation and long-term pipeline potential. Investors are closely monitoring unusual block trades and technical price action, viewing these signals as potential precursors to an M&A event despite historical skepticism regarding the company's independence.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos is currently generating intense debate among retail traders, with many participants expressing extreme bearish sentiment and anticipation of further downward price movement. The community remains deeply divided, with vocal skeptics labeling the project a "ghost chain" while contrarian traders continue to monitor support levels in search of potential re-entry points.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company’s FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S.&nbsp;</li><li>With this step, ART100 moves from regulatory clearance to active commercial availability, the company said.</li><li>Earlier, Inspira announced a non-binding term sheet for a proposed two-part deal to acquire an advanced liquid biopsy diagnostics business</li></ul>Shares of Inspira Technologies OXY (IINN) popped over 28% in pre-market trading on Monday after Israel’s largest health services provider approved the procurement of its FDA-cleared ART100 platform.<a href="https://stocktwits.com/symbol/IINN">IINN shares</a> gave up premarket gains and fell around 3% after the opening bell.&nbsp;The company secured approval from Clalit Health Services’ Medical Equipment Committee, allowing its INSPIRA ART100 system to be immediately procured and deployed across a healthcare network serving roughly 4.9 million members.<h2 class="st-heading-2">ART100 Regulatory Clearance</h2>With this step, ART100 moves from regulatory clearance to active commercial availability, marking a significant growth opportunity for Inspira and strong clinical validation.“By securing this approval, we are laying the foundation for potentially long-term, high-quality revenue. This validation from a world-class, data-driven health ecosystem serves as a powerful reference case as we accelerate our commercialization efforts in the U.S. and other global markets,” said Dagi Ben-Noon, CEO of Inspira Technologies.The company’s FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and for (Extracorporeal Membrane Oxygenation) ECMO procedures outside the U.S.<h2 class="st-heading-2">Top U.S. Medical Center Clears ART100&nbsp;</h2>In January, Inspira Technologies’ ART100 system completed clinical evaluation at a top U.S. academic medical centre and moved into the budgeted procurement stage. The system successfully treated about 30 patients across surgeries, transplants, and other critical procedures, leading to its adoption into routine clinical workflows.&nbsp;With the evaluation phase now closed, the hospital has begun an internal process to purchase multiple ART100 units, pending final budget approval.Earlier, Inspira announced a non-binding term sheet for a proposed two-part deal to acquire an advanced liquid biopsy diagnostics business. The transaction also includes a planned $15 million strategic equity investment.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes.The stock has shed around 25% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

Why Did IINN Stock Surge 28% In Pre-Market Today?

The company won approval from Clalit Health Services to deploy its INSPIRA ART100 system across a network of around 4.9 million members.

Equity

All You Need to Know About Inspira Technologies OXY (IINN) Rating Upgrade to Buy

Inspira Technologies OXY (IINN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Inspira Technologies OXY B.H.N. (IINN) on Friday announced that it has received U.S. Patent approval for the core technology of its ART500 device.The firm stated that the device is key to penetrating the $20 billion estimated market for advanced respiratory support. The newly received patent provides protection at least until the year 2043, covering key claims related to the ART500’s functionality, design, and clinical applications.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IINN">IINN stock</a> stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:577/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_22_at_2_07_05_PM_png_792c0ec45d.webp" alt="IINN's Sentiment Meter and Message Volume as of 2:07 p.m. ET on Aug. 22, 2025 | Source: Stocktwits" width="577" height="61"><figcaption>IINN's Sentiment Meter and Message Volume as of 2:07 p.m. ET on Aug. 22, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that they are loading up on the shares of the company.<stembedurl>https://stocktwits.com/VSWeWork/message/626246424</stembedurl>Another, however, sounded disappointed at the stock’s performance.<stembedurl>https://stocktwits.com/Kyavic77/message/626229410</stembedurl>The ART500 system is designed to provide extracorporeal oxygenation at low flow rates while maintaining patient safety and treatment efficiency. According to the firm, this targets a patient population that requires respiratory support but may not be sick enough for traditional, high-flow ECMO systems.Inspira CEO Dagi Ben-Noon <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/22/3137823/0/en/Inspira-Receives-U-S-Patent-Approval-for-the-ART500-Core-Technology-Key-Patent-Positions-the-Company-to-Dominate-20-Billion-Estimated-Market.html">said</a> that the patent has profound business implications for the company. “While our ART100 system is already generating commercial momentum, this move fortifies our future and gives us the clear runway…,” he said.Earlier this month, Inspira <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/19/3135699/0/en/Inspira-Secures-27-Million-Government-Binding-Purchase-Order-for-ART100-Systems-with-Full-Payment-in-2025.html">said</a> that a national ministry of health in Africa has placed a $27 million binding purchase order for its ART100 systems. The purchase order provides for full contractual payment scheduled for completion during 2025.IINN stock is up by 17% this year and by about 9% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/gary-black-believes-these-are-five-things-that-could-initiate-tesla-rally/chsZeukRdKP">Gary Black Believes These Are The Five Things That Could Initiate A Tesla Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

Inspira Technologies Receives US Patent Clearance For Core Technology Of Its ART500 Device: Retail Loads Up On The Stock 

The newly received patent provides protection at least until the year 2043, covering key claims related to the ART500 device’s functionality, design, and clinical applications.

Inspira Technologies Oxy B.H.N. Ltd. is a specialty medical device company, which engages in research, development, manufacturing, and marketing of proprietary life support technology with a vision to supersede traditional mechanical ventilators, or Mechanical Ventilation, which is the standard of care today for the treatment of acute respiratory failure. The company was founded by Dagi Shahar Ben Noon, Joe Hayon, and Udi Nussinovitch in July 2017 and is headquartered in Raanana, Israel.

Inspira Technologies Oxy B.H.N. Ltd

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

IINN
Inspira Technologies Oxy B.H.N. Ltd

Feed

News

Sentiment

Fundamentals

Info

Latest IINN News

IINNInspira Technologies Oxy B.H.N. Ltd